BioCardia, Inc. (NASDAQ:BCDA) Sees Significant Decrease in Short Interest

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 103,600 shares, a decrease of 5.4% from the November 15th total of 109,500 shares. Based on an average daily volume of 99,900 shares, the short-interest ratio is presently 1.0 days. Currently, 2.9% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research report on Wednesday.

BioCardia Stock Performance

Shares of BCDA opened at $2.00 on Thursday. The firm’s 50-day simple moving average is $2.32 and its 200 day simple moving average is $2.77. The firm has a market cap of $9.17 million, a P/E ratio of -0.48 and a beta of 1.25. BioCardia has a 52 week low of $1.84 and a 52 week high of $10.79.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.